Summary
IPO of Symbiotec Pharmalab is a mainboard IPO that will take place between 24th and 27th August 2026 in the range of ₹938 to ₹988.
Symbiotec Pharmalab is a company engaged in providing biopharmaceutical and biotechnological services for the manufacturing of pharmaceutical products such as corticosteroids and steroid hormones.
The IPO has a lot size of 15 shares, requiring a minimum investment of ₹14,820. Investors should consider valuation, regulatory risks, and market conditions before investing.
Symbiotec Pharmalab is making a ₹1,757 crore book-building initial public offer on the NSE & BSE. The offer includes a fresh issue worth ₹150 crore and an offer for sale up to ₹1,607 crore. The subscription period for the offer starts on 24 August 2026 and ends on 27 August 2026. The allotment date for the offer is set for 28 August 2026, followed by the issuance of shares on 31 August 2026 and listing on 1 September 2026.
The price band is between ₹938 and ₹988, and the lot size is 15 shares. Retail investors can apply for a minimum of one lot, which amounts to ₹14,820 at the top end of the price band. The current GMP reported is ₹0.
The lot size is 15 shares with a price band of ₹938 to ₹988. Retail investors can apply for a minimum of one lot, which is 15 shares and requires ₹14,820 at the top end of the price band. The S-HNI applications start from 14 lots, which are 210 shares, and require ₹2,07,480.
Symbiotec Pharmalab IPO Key Details
Here is a quick look at the important details of the Symbiotec Pharmalab IPO:
| IPO Open Date | 24 August, 2026 |
| Close Date | 27 August, 2026 |
| Face value | ₹2 per share |
| Price Band | ₹938 to ₹988 |
| Issue price | – |
| IPO Lot Size | 15 shares |
| Offer for sale | 1,62,65,181 shares of ₹2 (Upto ₹1607 share) |
| Fresh issue | 15,21,261 shares (Up to ₹150 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing at | BSE, NSE |
| Total Issue Size (₹ Crore) | 1,77186,442 shares (Upto ₹1,757 Cr) |
| Minimum Investment | ₹14,820 (15 shares) |
Symbiotec Pharmalab IPO Timeline
The key dates for the Symbiotec Pharmalab IPO are given below:
| Bidding Opens | 24 August, 2026 |
| Bidding Closes | 27 August, 2026 |
| Allotment Planned For | 28 August, 2026 |
| Refunds Start On | 28 August, 2026 |
| Share Credit to Demat | 1 September, 2026 |
| Listing Scheduled | 1 September, 2026 |
| Cut-off for UPI mandate | 5:00 PM on August 27, 2026 |
Symbiotec Pharmalab Key Performance Indicators (KPIs)
Symbiotec Pharmalab KPIs are presented in the following table:
| KPIs | FY 2026 | FY 2025 | FY 2024 |
| ROE (%) | 11.19% | 12.66% | 14.98% |
| ROCE (%) | 11.56% | 11.80% | 14.03% |
| Debt-Equity (times) | – | – | – |
| RoNW (%) | 9.48% | 11.79% | 13.90% |
| PAT Margin (%) | 12.60% | 12.80% | 13.83% |
| EBITDA Margin (%) | 26.59% | 27.26% | 24.48% |
| Price Book Value | 5.35 | 6.58 |
Symbiotec Pharmalab IPO Financials
Here is an overview of the company’s financial figures:
| Period | FY 2026 | FY 2025 | FY 2024 |
| Total Assets | 1780.79 | 1579.65 | 1294.79 |
| Revenue from operations | 869.15 | 751.55 | 716.25 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
(Amount in ₹ Crore)
Symbiotec Pharmalab IPO Subscription Status
| Date | QIB (Ex Anchor) | NII | Retail | EMP | Total |
|---|---|---|---|---|---|
| Aug 24 (Day 1) | 0.00 | 0.67 | 0.72 | 1.14 | 0.51 |
Symbiotec Pharmalab IPO Grey Market Premium
The listing date for Symbiotec Pharmalab is expected to be on 1 September, 2026, with a price range of ₹938-₹988 per equity share. Grey market premiums (GMPs) can fluctuate frequently because they are unofficial.
| GMP Date | GMP | Est. Listing Price (cap price + GMP) | Est. Profit | Last Updated |
|---|---|---|---|---|
| 24-08-2026 Open | ₹395 ▼ | ₹1383 (39.98%) | ₹5,925 | 24-Aug-2026 13:36 |
| 23-08-2026 | ₹409 ▼ | ₹1397 (41.40%) | ₹6,135 | 23-Aug-2026 23:34 |
| 22-08-2026 | ₹410 ▲ | ₹1398 (41.50%) | ₹6,150 | 22-Aug-2026 23:32 |
| 21-08-2026 | ₹345 ▲ | ₹1333 (34.92%) | ₹5,175 | 21-Aug-2026 23:37 |
| 20-08-2026 | ₹300 ▲ | ₹1288 (30.36%) | ₹4,500 | 20-Aug-2026 23:30 |
| 19-08-2026 | ₹220 ─ | ₹1208 (22.27%) | ₹3,300 | 19-Aug-2026 23:36 |
Note: GMP represents sentiment in the unofficial market and should not be considered an indication of assured listing returns.
Symbiotec Pharmalab IPO Reservation
The share allocation for each investor category is outlined below:
| Investor Category | Reservation |
| Market Maker | – |
| QIB | Not more than 50% of the Net offer |
| NIIs | Not less than 15% of the Net offer |
| Retail Investors | Not less than 35% of the Net offer |
| Total Shares | – |
Symbiotec Pharmalab IPO Lot Size
The applicable lot sizes for different investor categories are as follows:
| Application Type | Lots | Shares | Amount |
| Individual Investor – Minimum | 1 | 15 | ₹14,820 |
| Individual Investor – Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 | 1,020 | ₹10,07,760 |
Symbiotec Pharmalab IPO Anchor Investors
The allotment status of Symbiotec Pharmalab IPO is currently not yet available. As a result, information related to anchor bidding, share allocation, investment value and lock-in periods will be added once disclosed.
Symbiotec Pharmalab IPO Prospectus
For more information on the Symbiotec Pharmalab IPO, check the links below:
About Symbiotec Pharmalab IPO
Incorporation: 20 September, 2002
Managing Director: Anil Satwani
Symbiotec Pharmalab Limited is an innovator-focused pharma & biotech company specialising in APIs for corticosteroids and steroidal hormones. The company offers more than 60 APIs, including sterile and non-sterile corticosteroids and steroidal hormones, such as hydrocortisone, testosterone, and methylprednisolone.
It has manufacturing plants in Rau, Mhow, and Pithampur in Madhya Pradesh, capable of producing corticosteroid APIs and steroidal hormones and performing fermentation, biotransformation, and chemical synthesis. All its manufacturing plants are certified by leading regulatory authorities like FDA-US, WHO-GMP and EU-GMP. The company also serves customers in over 40 countries, in addition to providing CDMO services across both pharmaceutical and biotech platforms.
| Issue Registrar | MUFG Intime India Private Limited |
| Lead Manager | JM Financial Limited, Avendus Capital Pvt ltd, Motilal oswal Investment advisors limited, Nomura Financial Advisory & Securities Pvt Ltd. |
Symbiotec Pharmalab IPO Objectives
Funds received from the IPO will be directed towards the following purposes:
| Particulars | Amount (in ₹ Cr) |
| Working capital requirements | 112.5 |
| General corporate purposes |
Strengths of Symbiotec Pharmalab
- Corticosteroids and Steroidal Hormones APIs global leadership: Symbiotec is a world leader in this segment. Symbiotec has an API product line of more than 60 APIs, along with significant market share positions in Hydrocortisone, Testosterone, and Methylprednisolone.
- Manufacturing integration capabilities: Symbiotec has manufacturing capabilities that allow the company to control more areas of its production cycle through integrated capabilities in chemical synthesis, fermentation, biotransformation, and complex injectables.
- Widely distributed customers: Symbiotec has a customer base in more than 40 countries, with more than 200 customers, including prominent pharmaceutical companies in developed nations such as the US and Europe.
- Regulatory approvals: Symbiotec’s manufacturing facilities are certified by prominent regulators such as the US FDA, EU GMP, and WHO GMP. In addition, the company has 42 DMFs with the US FDA and 23 CEPs with the European Directorate for the Quality of Medicines and Healthcare EDQM.
- Advanced Research and Development and Technology capabilities: Symbiotec has research and development teams and technology engineers working on advanced technologies in chemical synthesis, biotechnology, precision fermentation and complex injectables.
Risks of Symbiotec Pharmalab
- High dependence on API products: The firm’s revenue is driven by its top five API products, which account for a major share of its total income. Any change in demand from the end market may affect its income.
- High customer dependency risk: Symbiotec is dependent on only a select few customers. The loss of any major customer or decrease in demand may hurt the firm.
- High regulatory risk: The pharmaceutical industry is highly regulated. Any non-compliance with standards can result in penalties and even company shutdowns.
- Risk of disruption in raw material supply: The company is reliant on imports and on raw materials sourced from a select few nations, such as China and the United States.
- High export and competitive risks: Symbiotec relies on its export markets for a significant share of its income. Any changes in exchange rates, regulatory policies or competition from Indian and Chinese firms may affect the company.
Symbiotec Pharmalab IPO Review
Investors can invest in the Symbiotec Pharmalab IPO, the IPO of a pharmaceutical company focused on producing steroid-based Active Pharmaceutical Ingredients (APIs), steroidal hormones, and their derivatives. The company has strong manufacturing facilities and operates across different international markets. Among other strengths, this company has manufacturing experience, regulatory approvals, and a diversified product line. Moreover, the company has been producing positive operating results and boasts an impressive EBITDA margin of 25.69% in fiscal year 2026.
However, there are also risks associated with this IPO, including regulatory risks, risks arising from product and customer dependency, raw material availability risk and global competition. Changes in pharmaceutical industry regulations and international market demand will affect the company’s operations. In addition, the investor needs to assess the valuation of this IPO relative to other pharmaceutical companies that are already listed. Therefore, the IPO can be considered by those investors who are interested in the pharmaceutical APIs industry.
Other Recent IPO List
Stay updated on upcoming IPOs in India and explore new investment opportunities.
| Credent Connect N Care IPO | Q&T Foods IPO |
| Fascinate Textiles IPO | Behari Lal Engineering IPO |
| Shiprocket IPO | Pramodini Medicare IPO |
| Milky Mist Dairy Food IPO | Dhoot Transmission IPO |
Symbiotec Pharmalab IPO FAQs
The mainboard book-built issue of the Symbiotec Pharmalab IPO is an IPO of approximately ₹1,757 crore. It consists of a fresh issuance of ₹150 crore and an offer for Sale from the shareholders. The price range is ₹938 to ₹988 per share.
Applications for the IPO can be made via a stockbroker using UPI or via the bank account using ASBA. Investors need to select the IPO, enter the required lot and bidding information, and approve the UPI mandate or the blocking of funds through ASBA.
The IPO offers an opportunity to invest in a pharmaceutical company with expertise in steroid APIs and overseas markets. Still, investors should take into account valuation, regulatory risk, customer concentration, and the company’s financial performance prior to investing.
Returns on IPO investment cannot be guaranteed, as the listing price depends on market conditions and investor interest. The GMP may give an unofficial prediction regarding the returns on the listing; still, it is subject to rapid change and not a reliable return predictor.
The initial public offering by Symbiotec Pharmalab will begin subscription on 24 August 2026 and end on 27 August 2026. The issue price band is set at ₹938 to ₹988 per share.
One lot for the Symbiotec Pharmalab share issue is 15 shares. With the maximum price of ₹988 per share, an investment of ₹14,820 would be required for one lot. Subscribers may apply for more lots in increments of 15 shares.
The allotment is scheduled to be finalised on 28 August 2026. The refund is started on 28 August 2026 and credit of shares to the allottees is started for 31 August 2026.
Listing of Symbiotec Pharmalab shares on the BSE and NSE will be on 1 September 2026. The exact listing price will be determined by market conditions on that day.
